Arctoris Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
42
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.97M
- Investors
-
14
Arctoris General Information
Description
Operator of an automated drug discovery platform intended to streamline the development of new drugs towards the clinic. The company leverages robotics and artificial intelligence to generate superior quality drug discovery data from a wide range of biochemical, cell-based and molecular biology assays conducted by robotics, enabling clients to make rapid decisions based on reliable, structured and well-annotated data, leading to faster and more efficient drug discovery programs.
Contact Information
Website
www.arctoris.comCorporate Office
- 120 East Olympic Avenue
- Oxfordshire, Milton Park
- Abingdon OX14 4SA
- England, United Kingdom
Corporate Office
- 120 East Olympic Avenue
- Oxfordshire, Milton Park
- Abingdon OX14 4SA
- England, United Kingdom
Arctoris Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 14-Aug-2023 | $4.97M | Completed | Generating Revenue | ||
| 8. Early Stage VC | 19-Nov-2020 | Completed | Generating Revenue | |||
| 7. Grant | 01-Jun-2020 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 01-Jan-2020 | Completed | Generating Revenue | |||
| 5. Seed Round | 01-Jul-2019 | Completed | Generating Revenue | |||
| 4. Grant | 01-Dec-2018 | Completed | Generating Revenue | |||
| 3. Grant | 01-Sep-2018 | Completed | Generating Revenue | |||
| 2. Seed Round | 01-Jun-2018 | $861K | $861K | Completed | Generating Revenue | |
| 1. Grant | 01-Nov-2017 | $185K | Completed | Startup |
Arctoris Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Seed | ||||||||
| Ordinary | 321,998 | $0.000128 | $12.75 | $12.75 | 1x | $12.75 | 16.88% | |
| Ordinary | 128,000 | $0.000128 | $6.41 | $6.41 | 1x | $6.41 | 6.71% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Arctoris Comparisons
Industry
Financing
Details
Arctoris Competitors (8)
One of Arctoris’s 8 competitors is Partek, a Corporate Backed or Acquired company based in Chesterfield, MO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Partek | Corporate Backed or Acquired | Chesterfield, MO | ||||
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| Dnastar | Private Debt Financed | Madison, WI | ||||
| Illumina | Formerly VC-backed | San Diego, CA | ||||
| Benchling | Venture Capital-Backed | San Francisco, CA |
Arctoris Patents
Arctoris Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230135701-A1 | Drug discovery using a pseudo concentration-response curve | Inactive | 29-Oct-2021 | ||
| US-20200199513-A1 | System and a method for producing an encapsulated cellular spheroid | Inactive | 19-Dec-2018 | ||
| US-20200172843-A1 | Apparatus for controlling an experimental temperature of an experimental material | Inactive | 04-Dec-2018 | ||
| US-20210147771-A1 | Apparatus for controlling an experimental temperature of an experimental material | Inactive | 04-Dec-2018 | ||
| CA-3126575-A1 | A system and method of performing a biological experiment with adaptive cybernetic control of procedural conditions | Active | 18-Oct-2018 | C12M41/48 |
Arctoris Signals
Arctoris Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Formic Ventures | Venture Capital | Minority | ||
| GK Goh Holdings | Fund of Funds | Minority | ||
| UK Innovation Agency | Government | Minority | ||
| Creative Destruction Lab | Accelerator/Incubator | |||
| Acequia Capital | Venture Capital | Minority |
Arctoris Investments (1)
Arctoris’s most recent deal was a Corporate Asset Purchase with Eli Lilly (Life Sciences Studio in San Diego, California). The deal was made on 12-Sep-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eli Lilly (Life Sciences Studio in San Diego, California) | 12-Sep-2024 | Corporate Asset Purchase | Buildings and Property |
Arctoris FAQs
-
When was Arctoris founded?
Arctoris was founded in 2016.
-
Where is Arctoris headquartered?
Arctoris is headquartered in Abingdon, United Kingdom.
-
What is the size of Arctoris?
Arctoris has 42 total employees.
-
What industry is Arctoris in?
Arctoris’s primary industry is Discovery Tools (Healthcare).
-
Is Arctoris a private or public company?
Arctoris is a Private company.
-
What is the current valuation of Arctoris?
The current valuation of Arctoris is .
-
What is Arctoris’s current revenue?
The current revenue for Arctoris is .
-
How much funding has Arctoris raised over time?
Arctoris has raised $16.4M.
-
Who are Arctoris’s investors?
Formic Ventures, GK Goh Holdings, UK Innovation Agency, Creative Destruction Lab, and Acequia Capital are 5 of 14 investors who have invested in Arctoris.
-
Who are Arctoris’s competitors?
Partek, Exscientia, Dnastar, Illumina, and Benchling are some of the 8 competitors of Arctoris.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process